| breast cancer - HER2-positive | |||
| es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HER2 positive - 2nd Line (L2) | |
| HER2 inhibitor | |||
| neratinib based treatment | |||
| neratinib | ExteNET | ||
| neratinib plus capecitabine | NALA NALA ... | ||
| pertuzumab based treatment | |||
| pertuzumab plus trastuzumab | PERTAIN | ||
| pertuzumab plus trastuzumab plus docetaxel | CLEOPATRA PUFFIN | ||
| trastuzumab based treatment | |||
| trastuzumab plus endocrine therapy | SYSUCC-002 | ||
| trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | GeparQuinto | ||
| tucatinib based treatment | |||
| tucatinib plus trastuzumab plus capecitabine | HER2CLIMB ... HER2CLIMB | ||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
